IASO Bio
IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.-China Clinical Development
First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated…